Current pharmacologic options for patients with Alzheimer's disease
Open Access
- 29 January 2003
- journal article
- Published by Springer Nature in Annals of General Hospital Psychiatry
- Vol. 2 (1) , 1
Abstract
BACKGROUND: The aim of the current study was to provide general practitioners with an overview of the available treatment options for Alzheimer's disease (AD). Since general practitioners provide the majority of medical care for AD patients, they should be well versed in treatment options that can improve function and slow the progression of symptoms. DESIGN: Biomedical literature related to acetylcholinesterase inhibitors (AChEIs) was surveyed. In the United States, there are four AChEIs approved for the treatment of AD: tacrine, donepezil, rivastigmine, and galantamine. There are other agents under investigation, but at present, AChEIs are the only approved drug category for AD treatment. MEASUREMENTS AND MAIN RESULTS: AD is becoming a major public health concern and underdiagnosis is a significant problem (with only about half of AD patients being diagnosed and only half of those diagnosed actually being treated). Clinical trials have demonstrated that patients with AD who do not receive active treatment decline at more rapid rates than those who do. CONCLUSIONS: Given that untreated AD patients show decline in three major areas (cognition, behavior, and functional ability), if drug treatment is able to improve performance, maintain baseline performance over the long term, or allow for a slower rate of decline in performance, each of these outcomes should be viewed a treatment success.Keywords
This publication has 70 references indexed in Scilit:
- Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChRActa Neurologica Scandinavica, 2000
- A Prospective PMS Study to Validate the Sensitivity for Change of the D-Scale in Advanced Stages of Dementia Using the NMDA-Antagonist MemantinePharmacopsychiatry, 2000
- Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 1999
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- The Neuropsychiatric InventoryNeurology, 1994
- Language Impairment and Rate of Cognitive Decline in Alzheimer's DiseaseDementia and Geriatric Cognitive Disorders, 1994
- Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's DiseaseNew England Journal of Medicine, 1990
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982